| DB ID | MyCo_6592 |
| Title | Serum (1 → 3) β-D-glucan assay for discrimination between Pneumocystis jirovecii pneumonia and colonization |
| Year | 2014 |
| PMID | 25066434 |
| Fungal Diseases involved | Pneumocystis jirovecii pneumonia |
| Associated Medical Condition | None |
| Genus | Pneumocystis |
| Species | jirovecii |
| Organism | Pneumocystis jirovecii |
| Ethical Statement | The ethical committee of Keio University School of Medicine approved the study protocol. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Japan |
| Cohort | We retrospectively evaluated data from 166 consecutive pa-tients who underwent bronchoalveolar lavage (BAL) for the diag-nosis of PCP at Keio University Hospital (Tokyo, Japan) during the period from April 2006 until November 2011. All of the patients had ground-glass opacities on chest computed tomography and clinical presentations such as fever, cough or dyspea. |
| Cohort No. | 166 |
| Age Group | None |
| P Value | p< 0.001 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Pneumocystis pneumonia (PCP) remains one of the most frequent opportunistic infections in immunocompromised patients, including those infected with human immunode ciency virus (HIV). Because Pneumocystis cannot readily be cultured in the laboratory, microscopic demonstration of the organism in respiratory specimens has been the gold standard for the diagnosis of PCP. The sensi- tivity of microscopic visualization of Pneumocystis is inconsistent and depends on the skill and experience of the observer. In addition, non- HIV patients, who develop PCP, are characterized with a lower fungal burden than HIV-infected patients with PCP. This lower fungal burden may result in false-negative results from microscopic examination. |
| Technique | Assay |
| Analysis Method | Serology Based |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | FDA approved Fungitell assay, KL-6 antibody, Lactate Dehydrogenase Assay, ELISA SAM antibody Assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
